TR 14531

Drug Profile

TR 14531

Latest Information Update: 08 Aug 2002

Price : $50

At a glance

  • Originator Tanabe Seiyaku
  • Class Anti-inflammatories; Antiasthmatics; Antirheumatics
  • Mechanism of Action Integrin alpha4beta1 antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • No development reported Inflammation

Most Recent Events

  • 16 Sep 1999 New profile
  • 16 Sep 1999 Phase-I clinical trials for Inflammation in USA (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top